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ABSTRACT 
The work was aim to formulate and evaluate mucoadhesive microspheres of Pioglitazone Hydrochloride for 
treatment of diabetes type-2 by combining  the potential advantages of mucoadhesion with controlled drug delivery 
using various ratio of polymers. Mucoadhesive microspheres were prepared by emulsion diffusion solvent 
evaporation technique. Microspheres were found  to be discrete, spherical and free flowing. They ranged in particle 
size from 73-125 μm , drug  release shown was  73.39-91% and mucoadhesiveness was 68-84%. Mainly in this 
Stirring speed affects particle size, Concentration of HPMC K100 affects drug release and concentration of 
Carbopol 934 affects mucoadhesiveness  The microspheres exhibits good mucoadhesive property in in-vitro wash 
off test and showed high drug entrapment efficiency. Pioglitazone Hydrochloride release from these microspheres 
was slowed, extended and depended on the type of polymer used. The work has demonstrated that among all the 
formulations of microspheres, particularly those of formulation F8 are promising candidates for the sustained release 
of  Pioglitazone Hydrochloride . 
 
Keywords: Mucoadhesive microspheres, Pioglitazone hydrochloride, Emulsion solvent diffusion evaporation 
method. 
INTRODUCTION 
 
Primary objectives of Controlled drug delivery system 
are to ensure the safety and to improve efficiency of drug 
as well as patient compliance. This is achieved by better 
control over plasma drug level and less frequent dosing. 
Controlled drug delivery occurs when a polymer, 
whether natural or synthetic, is judiciously combined 
with a drug or other active agent in such a way that the 
active agent is released from the material in a 
predesigned manner. Microspheres in general, have the 
potential to be used for targeted and controlled release 
drug delivery; but coupling of mucoadhesive properties 
to microspheres has additional advantages, e.g. efficient 
absorption and enhanced bioavailability of drug due to a 
high surface to volume ratio and much more intimate 
contact  with  the  mucus   layer .  
____________________________ 
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Mucoadhesive microspheres have gained considerable 
attention due to their ability to adhere to the mucus layer 
and release the loaded drug in a sustained manner. 
Mucoadhesive microspheres widely used because they 
release the drug for prolonged period, reduce frequency 
of drug administration and  improve  patient 
compliance[1,2,7].Diabetes is a syndrome characterized 
by disordered metabolism and inappropriately high 
blood sugar (hyperglycemia) resulting from either low 
levels of insulin effects coupled with inadequate levels of 
insulin secretion to complex state. Type II diabetes 
remains a difficult clinical challenge characterized by 
progressive insulin deficiency and frequent 
cardiovascular events requiring multiple therapeutic 
decisions. Over 30 million have now been diagnosed 
with diabetes in India. [3] 
A thiazolidinedione anti diabetic agent was selected as a 
drug candidate in the present study. Pioglitazone HCl has 
the pKa value of  4.9,  so it is largely  present  in  unionized  
form  and well  absorbed  from  the  acidic  pH   
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of the  stomach  than  the  basic pH condition of intestine. 
Also the drug is having short biological half life of 3 to 7 
h and hence is suitable for the sustained  release  dosage, 
control release (CR) products are needed for pioglitazone 
to prolong its duration of action and to improve patience 
compliance And localize the drug in  the stomach  for  an 
effective The site of absorption of Pioglitazone is in the 
stomach. Dosage forms that are retained in the stomach 
would increase the absorption, improve drug efficiency, 
and decrease dose requirements.  Controlled release 
formulation is also needed for pioglitazone for better 
control of blood glucose levels to prevent hypoglycemia 
and enhance clinical efficacy, to reduce g.i. disturbances 
and to enhance patient compliance.  Mucoadhesion has 
been a topic of interest in the design of drug delivery 
system to prolong the residence time of the dosage form 
at the site of application or the absorption and to 
facilitate intimate contact dosage form with the 
underlying absorption surface.  Therefore, mucoadhesive 
microspheres of   Pioglitazone Hydrochloride are 
promising candidate for delivery of for treatment of 
diabetes type-II.[4] .Thus present study was envisaged to 
formulate and in vitro evaluate the microspheres of 
Pioglitazone hydrochloride which release the drug in a 
sustained release manner. No controlled release 
formulations of Pioglitazone are available commercially.  
MATERIALS AND METHODS 
Pioglitazone Hydrochloride was a gift sample from 
Micro Labs Ltd, Bangalore. Carbopol 934 was  from  
Ana lab Fine chemicals Mumbai, HPMC K 100 was 
from Ana lab Fine chemicals Mumbai, Dichloromethane 
from Loba Chemie, Mumbai, Ethanol from Reserach 
Lab Fine Chem, Mumbai, Tween80 from Loba 
Chemie,Mumbai and n-hexane from  Research Lab Fine 
Chem,Mumbai .All the material and reagents are of 
analytical grade (A.R) 
Preparation of Mucoadhesive Microspheres [5] 
The mucoadhesive microspheres were prepared by using 
the emulsion solvent diffusion-evaporation method 
similar to one reported by kawashima et al . In the 
preliminary trials, weighed amount of drug (Pioglitazone 
hydrochloride), Carbapol 934 and HPMC K100M were 
dissolved in a mixture of Dichloromethane (DCM): 
Ethanol (ETN) (1:1) at room temperature. This solution 
was poured into 100ml distilled water containing 0.1% 
Tween 80 maintained at a temperature of 30-40ºC. The 
resultant emulsion was stirred with a propeller type 
agitator at  variable speed for 2-3 hours to allow  volatile 
solvent to evaporate. The resultant microspheres were 
filtered and dried. F1 toF15 were the preliminary batches 
prepared using different levels of Polymers. 
                     Table No.1: Formulation batches of Pioglitazone Hydrochloride microsphere [13,17] 
Batch code Variable Level in 
Coded Form 
X1 X2 X3 
F1 -1 -1 -1 
F2 1 -1 -1 
F3 -1 1 -1 
F4 1 1 -1 
F5 -1 -1 1 
F6 1 -1 1 
F7 -1 1 1 
F8 1 1 1 
F9 -1.682 0 0 
F10 1.682 0 0 
F11 0 -1.682 0 
F12 0 1.682 0 
F13 0 0 -1.682 
F14 0 0 1.682 
F15 0 0 0 
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Coded values Actual values 
X1 X2 X3 
-1 600 100 100 
0 950 200 200 
1 1300 300 300 
-1.682 361.37 31.82 31.82 
1.682 1538.63 368.18 368.18 
 
 
Where, X1= Stirring Speed (RPM),   X2= Conc. Of Carbapol 934(MG),   X3= Conc. Of  HPMC K100 (MG)  
 
Evaluation [4- 11] 
Infrared spectroscopic study (IR) 
IR absorption spectrum of Pioglitazone hydrochloride 
and its formulation evaluated by using Shimadzu FTIR 
spectrophotometer wherein 2 - 4 mg of drug sample was 
used. The resultant spectrum of the drug was compared 
with reference spectrum of Pioglitazone hydrochloride. 
Differential scanning calorimetry (DSC) 
The thermal behavior of Pioglitazone hydrochloride and 
its formulation was examined by DSC,using a Mettler 
differential scanning calorimeter. The system was 
calibrated with a high purity sample of Indium. PZ were 
scanned at the heating rate of 20°C/min over a 
temperature range of 70 to 300°C (Figure no). Peak 
transitions and enthalpy of fusion were determined for 
the samples using TA60 integration software 
Micromeritic properties of microspheres 
Flow properties: The flow properties of microsphere 
were studied by determining various parameters like the 
angle of repose, Carr’s index, and bulk density and 
tapped density. 
 
1) Production Yield (%) 
The production yield of microsphere was calculated 
using the weight of final product after drying with 
respect to the initial total weight of the drug and polymer 
used for preparation of microsphere and % production 
yield was calculated as per the formula mentioned 
below. 
Production yield: Wo / WT X100 
Where, WO = Practical mass (microspheres); 
WT = Theoretic mass (Polymer + Drug). 
 
2) Particle size analysis 
Particle size of different batches of microspheres was 
determined by optical microscopy. The projected 
diameter of microspheres from each batch was 
determined using ocular micrometer and stage 
micrometer equipped with optical microscope. Analysis 
observing the slide containing microspheres under the 
microscope.  
 
3) Drug entrapment efficacy 
50 mg of microsphere were taken and drug was extracted 
from microspheres by digesting for 24 h with 10 ml of 
0.1 N HCl. During this period the suspension was 
agitated. After 24 h the suspension was centrifuged at 
2000 rpm for about 3 min. The supernatant obtained was 
assayed spectrophotometrically for drug contents. 
Entrapment efficiency was calculated according to 
equation. 
Entrapment efficiency = (Practical drug content / 
theoretical drug content) × 100 
 
4) Surface morphology 
The surface morphology and shape were visualized by 
scanning electron microscopy (SEM). The samples were 
prepared by lightly sprinkling the microspheres powder 
on a double side adhesive tape which already shucked on 
aluminum stubs. The stubs were then placed into fine 
coat ion sputter for gold coating. After gold coating 
samples were randomly scanned for particle size and 
surface morphology. 
  
In-vitro mucoadhesivenes [10,12- 16] 
The mucoadhesive property of prepared microspheres 
was evaluated by in-vitro wash off method. A rat 
stomach mucosa was tied on the glass slide using a 
thread. About 100 microspheres were spread on to wet 
rinsed tissue specimen and prepared slide was hung on to 
one of the grooves of a USP tablet disintegration 
apparatus. By operating the disintegrating test apparatus 
the tissue specimen was given a slow regular up and 
down movement in the test fluid at 37±0.50C. At every 1 
h interval the equipment was stopped and the number of 
particles still adhering to tissue was counted. Percent 
mucoadhesion was given by the following formula. 
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% mucoadhesion = (no. of particle remains on mucosa/ 
no. of applied microsphere)×100  
 
In-vitro drug release 
 
The release rate of Pioglitazone Hydrochloride from 
microspheres was determined using United States 
Pharmacopeia (USP) dissolution testing apparatus 2 
(paddle type). The dissolution test was performed using 
900 ml of 0.1N HCl, at 37 ± 0.5°C and 50 rpm. A sample 
(10 ml) of the solution was withdrawn from the 
dissolution apparatus hourly for 12 h, and the samples 
were replaced with fresh dissolution medium to maintain 
the sick condition. The samples were filtered through a 
membrane filter and diluted to a suitable concentration 
with 0.1N HCl solution. Absorbance of these solutions 
was measured at 269 nm using a model 1700-E 
Shimadzu, double-beam UV spectrophotometer. 
  
RESULTS AND DISCUSSION 
Infrared spectroscopic study 
The spectrum of Pioglitazone HCl,  Formulation , 
Pioglitazone HCl& Carbapol 934 and Pioglitazone 
HCl& HPMC K100 was recorded in Shimadzu FT-IR  is 
shown in Fig. no.1,2&3. 
 
 
 
Fig No.1: FTIR Spectra of Pioglitazone Hydrochloride 
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Fig No.2: IR Spectra of Formulation 
 
A
B
C
D
 
A=Pioglitazone,  B=Pioglitazone+Carbapol934,  C=Pioglitazone+HPMCK100, D=Final formulation. 
Fig No.3: Drug-excipients compatibility studies 
 
Differential scanning calorimetry (DSC) 
The thermal behavior of PZ was examined by DSC, using a 
Mettler differential scanning calorimeter. The DSC 
thermogram of Pioglitazone HCl featured a single sharp 
melting endotherm, having a peak temperature of 200.13ºC, 
and Formulation having a peak temp. of 199.44 ºC .Figure 
no.4  shows the DSC Thermogram of Pioglitazone HCl. 
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Fig No.4: DSC thermogram of Pioglitazone HCl 
 
                                                       Fig No.5 : DSC thermogram of Formulation 
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1) Evaluation of micromeritic properties 
 The prepared formulations were evaluated for angle 
of repose, bulk density, tapped density, Carr’s index 
and hausner’s ratio. The results are shown in table no. 
2 
 
 
Table No. 2: Micromeritic properties of microspheres 
 
Formulation 
Code 
Angle of repose 
(θ) 
Bulk       
Density 
(gm/cm3) 
Tapped   
Density 
(gm/cm3) 
Carr’s Index 
(%) 
Hausner’s 
ratio 
F1 28.25±0.92 0.583±0.03 0.657±0.02 11.25±0.56 1.12±0.007 
F2 27.08±0.32 0.584±0.01 0.669±0.04 12.72±1.15 1.14±0.015 
F3 29.23±1.16 0.577±0.05 0.666±0.02 13.35±1.04 1.15±0.013 
F4 29.47±0.35 0.585±0.02 0.697±0.04 16.12±0.83 1.19±0.011 
F5 29.23±1.16 0.601±0.01 0.703±0.01 14.49±1.38 1.16±0.019 
F6 28.22±1.32 0.615±0,03 0.720±0.02 14.54±1.41 1.17±0.019 
F7 26.68±1.22 0.610±0.04 0.712±0.01 14.26±0.28 1.16±0.003 
F8 29.93±0.63 0.601±0.04 0.704±0.00 14.63±0.96 1.17±0.013 
F9 28.25±0.91 0.609±0.02 0.714±0.02 14.67±0.84 1.17±0.011 
F10 27.61±0.36 0.579±0.04 0.686±0.01 15.52±0.56 1.18±0.007 
F11 29.04±0.68 0.582±0.02 0.682±0.03 14.70±0.19 1.17±0.002 
F12 30.08±0.33 0.624±0.02 0.714±0.04 12.64±1.19 1.14±0.015 
F13 29.45±0.33 0.603±0.03 0.686±0.01 12.07±0.49 1.13±0.006 
F14 29.26±0.62 0.573±0.04 0.678±0.03 15.45±0.61 1.18±0.008 
F15 30.68±0.31 0.614±0.01 0.705±0.03 12.84±1.44 1.14±0.018 
 Mean ± S.D., n=3 
 
From the table  the  angle of repose, bulk density, tapped 
density; Carr’s index and hausner’s ratio were found to 
be within the limit as per reported literature. The Carr’s 
index and hausner’s ratio shows good flow properties for 
all the formulation. Also lower values for hausner’s ratio 
indicates good flow properties of the formulation 
Evaluation parameters of microspheres:- 
The prepared microspheres were evaluated for Percentage 
yield, drug entrapment efficiency, and average particle 
size. The results are shown in the table no.3 
 
Table No.3 : Evaluation parameters of microspheres 
 
Formulation 
Code 
Yield 
(%) 
Entrapment 
(%) 
Particle size 
(µm) 
F1 75.83±2.81 64.43±1.94 94±2.51 
F2 65.23±2.80 70.70±1.01 75±2.30 
F3 70.36±2.70 76.36±2.15  105±2.08 
F4 78.53± 2.85 
 
80.53±0.86 
 
83±3.60 
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F5 64.86±2.73 65.37±1.67 100±3.21 
F6 75.73±2.30 71.03±0.75 77±2.08 
F7 80.26±2.66 81.76±1.55 100±2.51 
F8 78.63±2.01 80.63±1.16 80±3.0 
F9 73.33±2.90 68.26±1.20 125±3.05 
F10 79.36± 2.69 76.93±1.35 73±2.88 
F11 73.43±2.75 78.03±1.40 94±3.21 
F12 68.70±3.02 86±2.83 98±3.0 
F13 63.43±2.71 82.70±1.93 93±2.64 
F14 76.40±2.85 78.93±1.1083 97±2.0 
F15 67.80±3.03 76.76±1.81 96±3.05 
 
 
From the table no 3, the percent yields of the all 
formulations were found to be in the range of 64.86±2.73 
to 84.43±2.71.  
The low percentage yield in some formulations may be 
also due to microspheres lost during the washing 
process. 
The drug entrapment efficiency was found to be in the 
range of 64.43±1.94 to 86 ±2. 6.  
The mean particle sizes of the drug loaded microspheres 
were carried out by optical microscopy. The mean 
particle size might be affected by mainly Stirring speed 
&different types of polymers which are used in 
preparation of microspheres.  
The average particle size of microspheres was found to 
be in the range of73±2.88 to 125±3.05 µm. 
 The particle size decreases as the stirring speed 
increases and particle size increases as the polymer 
concentration increases formation of the large droplets 
during addition of polymers. 
From the result, it was observed that the drug entrapment 
efficiencies increased progressively with increasing the 
concentration of copolymer resulting in the formation of 
larger microspheres entrapping the greater amount of the  
 
 
drug, this may be attributed to the greater availability of 
carbopol coating on the microsphere. 
  
In Vitro drug release 
 
The dissolution studies were performed in a fully 
calibrated eight station dissolution test apparatus (37 ± 
0.5oC, 50 rpm) using the USP rotating basket method in 
0.1 N HCl buffer media (pH 1.2, 900 ml).  
Microsphere formulation equivalent to 30 mg 
Pioglitazone for each formulation was employed in all 
dissolution studies.  
The samples of 5 ml each were withdrawn at 
predetermined time intervals and replenished 
immediately with the same volume of fresh pre-warmed 
0.1N HCl buffer maintaining sink condition throughout 
the experiment. The aliquots, following suitable dilution, 
were analyzed spectrophotometrically at 270 nm.  
The concentrations of PZ in the test samples were 
calculated using a regression equation of the calibration 
curve in 0.1N HCl buffer of pH 1.2 . 
In the table below highest drug release observed was  
91.17%, 90.06%, 87.43%, 86.99% for  F14 ,F8, F5 ,F10 
respectively. 
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                                               Table No .4: In vitro drug release of microspheres 
 
Time 
(hr) 
                                                          %DRUG RELEASE  
F1 F2 F3 F4 F5 F6 F7 F8 F9 F1O F11 F12 F13 F14 F15  
                
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
                
1 4.75 5.06 4.96 6.51 7.70 6.72 3.41 5.79 8.53 6.15 10.13 6.51 6.82 5.12 5.11  
                
2 6.21 8.75 9.27 11.34 14.97 11.39 10.1 11.13 16.01 10.9 15.27 11.34 13.41 10.31 10.62  
                
3 10.16 15.44 15.29 16.90 22.23 18.45 15.44 16.53 25.81 19.12 20.48 15.60 20.16 15.65 16.34  
4 15.66 20.79 21.18 24.29 31.74 24.32 21.21 22.61 31.28 26.0 31.22 21.83 26.91 23.77 22.34  
                
5 23.65 30.91 27.30 31.14 41.51 32.12 29.51 30.04 36.59 33.00 39.23 29.99 32.33 31.76 30.67  
6 31.18 36.44 33.84 38.21 47.66 39.46 36.18 36.80 43.05 40.49 46.52 36.23 37.13 39.24 34.16  
                 
7 37.85 41.86 41.65 44.98 53.15 50.11 42.53 44.61 51.76 48.04 53.15 42.07 43.07 46.74 42.85  
                
8 46.53 50.30 50.34 51.30 62.63 58.66 50.35 53.26 60.25 58.50 60.09 48.44 50.06 61.81 50.35  
                
9 51.87 57.70 57.08 58.65 68.24 67.79 58.69 62.64 67.60 68.82 67.51 57.19 55.09 67.47 60.09  
10 64.25 67.71 62.47 66.02 74.22 76.09 67.92 72.60 73.85 73.82 72.97 66.00 62.45 72.82 67.51  
                 
11 69.14 74.21 67.77 70.23 81.04 83.38 75.73 78.11 79.47 80.89 79.47 74.15 67.80 83.36 72.92  
                
12 74.39 83.09 73.96 77.10 87.43 89.01 86.20 90.06 84.95 86.99 86.44 82.26 73.72 91.17 83.30  
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                                               Fig No.6:In vitro drug release profile of  F1-F15 
 
 
In vitro mucoadhesiveness 
 
The mucoadhesive properties of the microspheres were 
evaluated by the in vitro wash-off test as reported by 
Lehret et al. A 1 cm x 1 cm piece of rat stomach mucosa 
was tied onto a glass slide (3 inch x 1 inch) using a 
thread. Microspheres were spread onto the wet, rinsed, 
tissue specimen, and the prepared slide was hung onto 
one of the groves of a USP tablet disintegrating test 
apparatus. The disintegrating test apparatus was operated  
 
 
such that the tissue specimen was given regular up and 
down movements in a beaker containing the simulated 
gastric fluid (pH 1.2). At the end of every time interval, 
the number of microspheres still adhering on to the tissue 
were counted and there adhesive strength was determine 
using the following formula. 
Percent mucoadhesion =  
(Weight of adhered microsphere /Weight of applied 
microspheres) ×100 
Table No. 5 : In Vitro Mucoadhesiveness 
 In Vitro MUCOADHESIVENESS 
TIM
E 
(HR
S) 
                                                                     %  MUCOADHESIVENESS  
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15  
1 88.9
7 
95.6
3 
95.1
6 
96.5
3 
95.6
3 
98.6
0 
97.8
0 
95.5
3 
92.6
7 
94.3
6 
85.7
3 
98.6
7 
95.7
3 
90.8
3 
88.9
0 
 
                 
2 85.4
3 
89.5
0 
92.3
6 
93.4
3 
89.5
0 
92.5
3 
94.8
0 
93.4
3 
89.7
3 
92.5
0 
82.5
7 
95.7
3 
92.5
7 
88.6
0 
86.9
0 
 
4 82.7
0 
85.3
7 
89.7
6 
90.7
7 
85.3
7 
85.3
3 
91.2
3 
89.7
7 
85.9
0 
89.3
7 
78.7
3 
92.9
0 
86.7
3 
85.5
0 
83.5
0 
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6 79.7
3 
81.4
3 
87.8
6 
88.6
7 
78.4
3 
82.9
3 
88.1
3 
87.6
7 
81.7
7 
86.3
4 
74.5
3 
90.7
7 
80.5
3 
83.3
3 
81.5
3 
 
                
8 76.3
3 
78.3
0 
84.2
4 
86.3
3 
74.3
0 
78.1
6 
85.1
3 
85.3
3 
78.4
7 
83.3
0 
72.0
7 
88.4
7 
77.0
7 
80.4
7 
79.1
0 
 
                 
10 73.7
7 
76.0
3 
81.2
6 
84.5
3 
73.0
3 
76.8
0 
83.0
0 
81.5
3 
74.6
3 
81.0
3 
70.9
0 
86.6
3 
74.9
0 
78.1
3 
78.9
6 
 
                
12 69 72.9
7 
78 82 70 75.3
3 
80.0
0 
83 72 79 68 84 72 77 75  
 
From the above table it is concluded that F12,F8,F7 having highest mucoadhesiveness of 84%,83%,80%respectively. 
 
 
 
                                                  Fig No.7: In vitro mucoadhesiveness profile  of F1-F15 
 
Scanning Electron Microscopy: Morphology of 
microsphere batch was examined by scanning electron 
microscopy. In University of pune, SEM model JEOL 
JSM 6360A the top view of the microspheres showed a 
spherical structure with a slight rough surface 
morphology 
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                                     Fig No.8: SEM images of Pioglitazone hydrochloride microspheres 
Annova study                                                 Table No.6: Study of responses 
 
Batch code Variable Level in 
Coded Form 
Particle size 
(Y1) (µm) 
  %Drug       
Release (Y2) 
(%) 
Mucoadhesiveness(Y3) 
(%) 
X1 X2 X3 
F1 -1 -1 -1 94 74.36 69 
F2 1 -1 -1 73 83.09 72 
F3 -1 1 -1 105 73.96 78 
F4 1 1 -1 83 77 82 
F5 -1 -1 1 100 87.08 70 
F6 1 -1 1 77 89 75 
F7 -1 1 1 100 86.59 80 
F8 1 1 1 80 90.69 83 
F9 -1.682 0 0 125 84.96 75 
F10 1.682 0 0 75 86.96 79 
F11 0 -1.682 0 94 86.39 68 
F12 0 1.682 0 98 82.48 84 
F13 0 0 -1.682 93 73.39 72 
F14 0 0 1.682 97 91 77 
F15 0 0 0 96 83.36 75 
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Analysis of data by design expert software [17] 
A RSM design was selected and the 3 factors were 
evaluated at 3 levels, respectively (Table 6). Stirring 
speed(X1), Conc.of carbapol934(X2) and HPMC 
K100M (X3)  and were selected as independent variables 
and the dependent variables were particle size,  percent 
drug release and mucoadhesiveness. The data obtained  
 
 
 
were treated using Stat Ease Design Expert 8.0.7.1 
software and analyzed statistically using analysis of 
variance (ANOVA) .The data were also subjected to 3-D 
response surface methodology to study the interaction of  
)Stirring speed(X1), Conc.of carbapol934(X2) and 
HPMC K100M (X3) 
  
 
                                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                   Fig No.9:3D Surface plot of particle size 
 From the above graph it is concluded that as stirring speed increases particle size decreases and particle size increases 
as the concentration of carbapol934 increases. 
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Minimum particle size :73µm 
Design-Expert® Software
Factor Coding: Actual
particle size 
Design points above predicted value
125
73
X1 = A: stirring speed
X2 = B: conc.of carbapol934
Actual Factor
C: conc.of hpmc k 100 = 200.00
100.00  
150.00  
200.00  
250.00  
300.00  
  600.00
  670.00
  740.00
  810.00
  880.00
  950.00
  1020.00
  1090.00
  1160.00
  1230.00
  1300.00
70  
80  
90  
100  
110  
  
p
a
rt
ic
le
 s
iz
e
  
 
  A: stirring speed    B: conc.of carbapol934  
 
Asian Pac. J. Health Sci., 2014; 1(3): 177-192                                                                  ISSN: 2349-0659                              
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Wattamwar et al ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2014; 1(3): 177-192 
www.apjhs.com     Page 190 
 
 
                                               Fig No.10: 3D Surface plot of drug release 
As seen in above graph ,as concentration of HPMC K100 and stirring speed increases drug release increases. 
 
 
Maximum drug release: 91 % 
Minimum drug release: 73.39% 
      
                                                   Fig No.11: 3D Surface plot of mucoadhesiveness 
In the above graph, mainly concentration of carbapol934 affects   mucoadhesiveness, as the concentration of 
carbapol934 increases mucoadhesiveness increases, stirring speed has less affected. 
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CONCLUSION 
 
The mucoadhesive microspheres of Pioglitazone 
hydrochloride were prepared by solvent diffusion 
evaporation method and optimized using the Response 
surface method factorial design. The concentration of 
Carbapol934 and HPMC K100 had significant impact on 
mucoadhesiveness and drug release. The results of RSM 
factorial design revealed that the   Stirring speed (X1) , 
Conc. Of Carbapol 934 (X2) & Conc. Of HPMC K 
100significantly affected the dependent variables such 
as,particle size of microspheres, drug release and 
mucoadhesiveness. Evaluation of formulations, chosen 
as optimal from grid searches, indicated that the 
formulation F8 fulfilled maximum requisites because of  
optimumparticlesize,better muco adhesiveness  strength, 
& sustained release of the drug .                                                       
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